Field Medical raises $40M for PFA in ventricular tachycardia

Field Medical, a startup founded by Farapulse creator Steven Mickelsen, has raised $40 million to support its development of a pulsed field ablation (PFA) system targeting ventricular tachycardia (VT), a life-threatening arrhythmia. The funding will support first-in-human trials for VT and atrial fibrillation (AFib), as well as scaling for a pivotal VT study. Unlike competitors Boston Scientific and Medtronic, who focus primarily on AFib with their PFA systems, Field is differentiating itself by prioritizing VT — a condition with limited drug treatment options and significant unmet need.

PFA is a newer ablation technology that uses electrical pulses instead of heat or cold, resulting in more precise tissue destruction with reduced collateral damage. Mickelsen, who previously sold his company Farapulse to Boston Scientific, aims to bring the same innovation to VT with Field’s FieldForce system. The company, based in Cardiff-by-the-Sea, California, is also positioning itself to eventually compete in the broader arrhythmia market, including AFib, against giants like J&J, Abbott, Medtronic, and Boston Scientific.